EssilorLuxottica Société anonyme (ENXTPA:EL) took the stage at the 2026 UBS Luxury Conference on 16 September, presenting its eyewear and vision care portfolio to a luxury-focused investor audience.
The UBS Luxury Conference appearance comes after a tough stretch for EssilorLuxottica Société anonyme’s shareholders, with the stock at €144.5 and the year to date share price return down 45.57%, contributing to a 46.10% decline in 1-year total shareholder return even as shorter term selling pressure has eased slightly in recent sessions.
Compare EssilorLuxottica Société anonyme’s current pressure with other potential recovery stories by scanning our handpicked 173 high quality undervalued stocks list that combines solid cash flows with stronger balance sheets.
EssilorLuxottica Société anonyme runs a broad, profitable eyewear and vision care platform, yet the share price has retreated sharply this year. Does that gap signal a fair reset or a mispriced global leader hiding in plain sight?
Most Popular Narrative: 40% Undervalued
EssilorLuxottica Société anonyme closed at €144.5, while the most followed fair value narrative sits at about €242.65, implying a sizeable valuation gap that hinges on how convincingly the business can translate its expansion and product pipeline into future earnings.
Strong pipeline of innovation in myopia management solutions (Stellest 2.0, DOT technology) and leadership in addressing rising vision disorders among children globally positions EssilorLuxottica to capture outsized growth from increasing myopia incidence, directly supporting future revenue and market share gains.
See why 37 investors see EssilorLuxottica Société anonyme as 40% undervalued.
Result: Fair Value of €242.65 (UNDERVALUED)
Still, the EssilorLuxottica Société anonyme story can be knocked off course if smart eyewear adoption lags expectations or if tariff and inflation pressures keep squeezing margins.
Find out about the key risks to this EssilorLuxottica Société anonyme narrative.
Another View on EssilorLuxottica Société anonyme’s Valuation
The fair value narrative leans heavily on future earnings power, yet the current P/E of 26.6x tells a different story. EssilorLuxottica Société anonyme trades close to the European Medical Equipment average of 26.7x and below the peer group at 34.8x, while the fair ratio of 24.4x signals some valuation stretch.
This combination of slight expensiveness relative to the fair ratio and lower levels versus peers raises a simple question for you: is this a quality stock priced for a modest reset, or a premium that still needs more earnings proof before it re-rates?
See what the numbers say about this price — find out in our valuation breakdown.
ENXTPA:EL P/E Ratio as at Sep 2026 Next Steps
Sentiment around EssilorLuxottica Société anonyme is clearly split, with clear risks on one side and meaningful potential rewards on the other. Act quickly, review the data for yourself, then weigh up the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond EssilorLuxottica Société anonyme?
Do not stop with a single stock. Use broader idea lists to pressure test your thesis, spot fresh angles, and keep your watchlist genuinely competitive.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include EL.PA.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com